Recombinant Human NPC1 protein, His/FLAG-tagged

Cat.No. : NPC1-1339H
Product Overview : Recombinant Human NPC1(Arg372-Phe622) fused with His/FLAG tag at N-terminal was expressed in HEK293.
Availability July 03, 2025
Unit
Price
Qty
  • Specification
  • Gene Information
  • Related Products
  • Citation
  • Download
Species : Human
Source : HEK293
Tag : Flag&His
Protein Length : Arg372-Phe622
Predicted N Terminal : His
Form : Lyophilized from sterile PBS, pH 7.4.1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.2. Please contact us for any concerns or special requirements.
Molecular Mass : The recombinant human NPC1 consists 278 amino acids and predicts a molecular mass of 32 kDa.
Endotoxin : < 1.0 EU per μg protein as determined by the LAL method.
Purity : > 95 % as determined by SDS-PAGE
Stability : Samples are stable for up to twelve months from date of receipt at -70 centigrade
Storage : Store it under sterile conditions at -20 centigrade to -80 centigrade. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution : A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
Shipping : In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Publications :
Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein (2018)
Gene Name NPC1 Niemann-Pick disease, type C1 [ Homo sapiens ]
Official Symbol NPC1
Synonyms NPC1; Niemann-Pick disease, type C1; Niemann-Pick C1 protein; NPC; FLJ98532;
Gene ID 4864
mRNA Refseq NM_000271
Protein Refseq NP_000262
MIM 607623
UniProt ID O15118
Chromosome Location 18q11-q12
Pathway Lysosome, organism-specific biosystem; Lysosome, conserved biosystem;
Function hedgehog receptor activity; protein binding; receptor activity; sterol transporter activity; transmembrane signaling receptor activity;

Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein

Journal: Immunity    PubMed ID: 30029854    Data: 2018/8/21

Authors: Pavlo Gilchuk, Natalia Kuzmina, James E. Crowe

Article Snippet:Alexa Fluor 647 NHS ester , ThermoFisher , Cat# A37573.Alexa Fluor 647 NHS ester , ThermoFisher , Cat# A37573.. Recombinant NPC1 protein, His/FLAG-tagged , Creative BioMart , Cat# NPC1-1339H.. FluoSpheres NeutrAvidin-Labeled Microspheres , ThermoFisher , Cat# F-8776.FluoSpheres NeutrAvidin-Labeled Microspheres , ThermoFisher , Cat# F-8776.

EBOV-515 and -520 Target Both Intact GP and Cleaved GP CL Intermediate to Neutralize the Virus (A) Binding curves for EBOV-515 or -520 using Jurkat-EBOV GP or Jurkat-EBOV GP CL . Fluorescently labeled mAbs were incubated with cells, and binding was assessed by flow cytometric analysis. (B) Neutralization curves for EBOV-515 or -520 or control mAbs 13C6 or BDBV317 using rVSV/EBOV-GP or rVSV/EBOV-GP CL . (C) Capacity of mAbs to inhibit NPC1-C binding to GP CL . mAbs were incubated with Jurkat-EBOV GP CL , then with purified NPC1-C tagged with FLAG-epitope. Complexes were detected with anti-FLAG Abs by flow cytometry. (D) Competition binding of EBOV-520 with RBS-specific mAbs MR72 or MR78 was assessed using Jurkat-EBOV GP CL . mAb binding was analyzed by flow cytometry. Numbers indicate the percent binding of the second fluorescently labeled mAb (2) in the presence of the first unlabeled mAb (1), compared to binding of second labeled mAb alone (dotted line). (E) Binding curves of fluorescently labeled mAb EBOV-515 or -520 to Jurkat-EBOV GP in the presence of a fixed concentration of unlabeled mAb EBOV-437 or -442. Mean ± SD of triplicates are shown, and data in (A) and (C)–(E) are representative of two independent experiments. Data in (B) represent one experiment. See also Figure S4 .

EBOV-515 and -520 Target Both Intact GP and Cleaved GP CL Intermediate to Neutralize the Virus (A) Binding curves for EBOV-515 or -520 using Jurkat-EBOV GP or Jurkat-EBOV GP CL . Fluorescently labeled mAbs were incubated with cells, and binding was assessed by flow cytometric analysis. (B) Neutralization curves for EBOV-515 or -520 or control mAbs 13C6 or BDBV317 using rVSV/EBOV-GP or rVSV/EBOV-GP CL . (C) Capacity of mAbs to inhibit NPC1-C binding to GP CL . mAbs were incubated with Jurkat-EBOV GP CL , then with purified NPC1-C tagged with FLAG-epitope. Complexes were detected with anti-FLAG Abs by flow cytometry. (D) Competition binding of EBOV-520 with RBS-specific mAbs MR72 or MR78 was assessed using Jurkat-EBOV GP CL . mAb binding was analyzed by flow cytometry. Numbers indicate the percent binding of the second fluorescently labeled mAb (2) in the presence of the first unlabeled mAb (1), compared to binding of second labeled mAb alone (dotted line). (E) Binding curves of fluorescently labeled mAb EBOV-515 or -520 to Jurkat-EBOV GP in the presence of a fixed concentration of unlabeled mAb EBOV-437 or -442. Mean ± SD of triplicates are shown, and data in (A) and (C)–(E) are representative of two independent experiments. Data in (B) represent one experiment. See also Figure S4 .

Not For Human Consumption!

Inquiry

  • Reviews (0)
  • Q&As (0)

Customer Reviews

Write a review

Ask a Question for All NPC1 Products

Required fields are marked with *

My Review for All NPC1 Products

Required fields are marked with *

0
cart-icon